These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 15135735

  • 1. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.
    Harandi AM.
    J Clin Virol; 2004 Jul; 30(3):207-10. PubMed ID: 15135735
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
    Tengvall S, Harandi AM.
    J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
    [Abstract] [Full Text] [Related]

  • 4. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S, O'Hagan D, Harandi AM.
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [Abstract] [Full Text] [Related]

  • 5. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
    Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA.
    J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
    [Abstract] [Full Text] [Related]

  • 6. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
    Gill N, Rosenthal KL, Ashkar AA.
    J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
    [Abstract] [Full Text] [Related]

  • 7. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
    Kwant A, Rosenthal KL.
    Vaccine; 2004 Aug 13; 22(23-24):3098-104. PubMed ID: 15297061
    [Abstract] [Full Text] [Related]

  • 8. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
    Sajic D, Ashkar AA, Patrick AJ, McCluskie MJ, Davis HL, Levine KL, Holl R, Rosenthal KL.
    J Med Virol; 2003 Dec 13; 71(4):561-8. PubMed ID: 14556270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.
    Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL.
    J Virol; 2003 Aug 13; 77(16):8948-56. PubMed ID: 12885911
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ, Patrick A, Moss RB, Rosenthal KL.
    J Virol; 2005 Jan 13; 79(1):393-400. PubMed ID: 15596832
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
    Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM.
    J Virol; 2006 Jun 13; 80(11):5283-91. PubMed ID: 16699008
    [Abstract] [Full Text] [Related]

  • 18. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection.
    Hendrickson BA, Guo J, Brown I, Dennis K, Marcellino D, Hetzel J, Herold BC.
    Virology; 2000 May 25; 271(1):155-62. PubMed ID: 10814580
    [Abstract] [Full Text] [Related]

  • 19. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
    Lindqvist M, Persson J, Thörn K, Harandi AM.
    J Immunol; 2009 May 15; 182(10):6435-43. PubMed ID: 19414797
    [Abstract] [Full Text] [Related]

  • 20. Innate immunity to herpes simplex virus type 2.
    Duerst RJ, Morrison LA.
    Viral Immunol; 2003 May 15; 16(4):475-90. PubMed ID: 14733735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.